Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy—results from the prospective multi-center study BRENDA II
- 241 Downloads
This study examined which patient- and physician-related factors influence guideline violations in adjuvant chemotherapy.
Patients and methods
In a prospective multi-center cohort study, patients with primary breast cancer were sampled consecutively over a period of four years (2009–2012). Patients completed a questionnaire prior to surgery and prior to adjuvant therapy. This questionnaire assessed health-related quality of life (QoL) using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, psychiatric co-morbidity with the Patient Health Questionnaire (PHQ), demographic characteristics (age, education), and the intensity of fear for chemotherapy.
After surgery, a multi-professional team discussed recommendation for adjuvant chemotherapy, and this decision was documented in a database together with the indication for chemotherapy according to the German S3 guideline. This multi-professional team was blinded to that algorithm-based decision. Six months later, it was documented whether the patient had received adjuvant chemotherapy or not.
Altogether, 857 patients were included in the study. In 391 of these patients, the tumor board (TB) decided to recommend chemotherapy. The most important reasons for not recommending chemotherapy were somatic co-morbidity not allowing adjuvant chemotherapy and age >75 years.
Of these 391 patients, 73 (19 %) patients eventually did not receive chemotherapy. Deviations from the initial therapy decision were more frequent in older patients (≥75 years) with poor QoL. If the QoL was good, higher age was not related to deviation. There was some evidence that patients with higher education less frequently received chemotherapy (CT). Furthermore, if patients were very afraid of chemotherapy, deviations from the initial therapy decision were more likely. Co-morbidity and fear of CT were not related to the likelihood of deviating from the initial therapy decision.
Nineteen percent of patients eventually did not receive chemotherapy, despite guideline and TB recommendations. In these patients, this mainly occurred in association with poor QoL in elderly patients >75 years old. In the group with a chemotherapy recommendation, patients’ fear of chemotherapy is another factor preventing patients from undergoing adjuvant chemotherapy.
KeywordsBreast cancer Compliance Chemotherapy Co-morbidity Guideline
Compliance with ethical standards
This study and the BRENDA project have been approved by the ethics committee of the University of Ulm.
Conflict of interest
The authors declare that they have no competing interests.
This work was supported by the German Federal Ministry of Education and Research (BMBF-Grant-01ZP0505).
- 1.Robert-Koch-Institute, Breast cancer incidence in Germany 2014, http://www.rki.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html. Accessed 1 Jul 2015.
- 3.Van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ, National evaluation team for breast cancer screening in Netherlands study groups (NETB) (2013) Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. Eur J Cancer 49(16):3517–25CrossRefPubMedGoogle Scholar
- 5.Kowalski C, Ferencz J, Brucker SY, Kreienberg R, Wesselmann S. Quality of care in breast cancer centers: results of benchmarking by the German Cancer Society and German Society for Breast Disease. Breast 2014; doi: 10.1016/j.breast.2014.11.014
- 9.Wolters R, Wöckel A, Janni W, Novopashenny I, Ebner F, Kreienberg R et al (2013) Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival and is there a role for guideline-adherent adjuvant therapy? A retrospective multi-center cohort study of 8,935 patients. Breast Cancer Res Treat 142(3):579–90CrossRefPubMedGoogle Scholar
- 14.Löwe B, Spitzer RL, Zipfel S, Herzog W (2002) PHQ-D Gesundheitsfragebogen für Patienten. Pfizer, Manual. KarlsruheGoogle Scholar
- 15.Spitzer RL, Williams J, Kroenke K (1999) Prime MD today. Evaluation of metal disorders. Pfizer, New YorkGoogle Scholar
- 20.Kreienberg R, Kopp I, Albert U, Bartsch H, Beckmann MW, Berg D, et al. Interdisciplinary S3 guideline for diagnosis and therapy of breast cancer in women. German cancer society 2008Google Scholar
- 25.Harbeck N, Blettner M, Hadji P, Jakisch C, Lück HJ, Windermuth-Kieselbach C et al (2013) Patient’s Anastrozole Compliance to Therapy (PACT) program: baseline data and patient characteristics from a population-based, randomized study evaluating compliance to aromatase inhibitor therapy in postmenopausal women with hormone-sensitive early breast cancer. Breast Care (Basel) 8(2):110–20CrossRefGoogle Scholar